Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Exelixis, Inc.
Give agency credit for beating the expiration date after missing it in previous renewals.
Seattle biotech raised $36m series A in March, now obtains glaucoma and AMD drug candidates along with delivery technology. Alligator, Orion partner on bispecific antibodies for cancer.
The company set a $26,400 per month list price for the HIF-2α inhibitor in its first US FDA-approved indication of VHL disease-associated tumors, but the drug is being studied in broader populations.
With full-year 2020 and Q1 sales down due to pandemic, the company celebrates the PD-1 therapy’s growth in Q2. CAR-T products Breyanzi, Abecma are off to solid launches but face manufacturing hurdles.
- Other Names / Subsidiaries
- X-Ceptor Therapeutics, Inc.